JPRN-jRCT2051210165招募中1 期
A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients
Tawara Shunsuke0 个研究点目标入组 80 人开始时间: 2022年2月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •*18 years of age or older
- •* Metastatic colorectal cancer; pathologically confirmed adenocarcinoma of the colon or rectum
- •* ECOG performance status of 0 or 1
- •* The most recent laboratory findings (including for liver and kidney) within 14 days prior to randomization remain within acceptable ranges Willingness of the patient and the sexual partner to use a highly effective
- •contraceptive method during the course of the study
- •* Able to sufficiently understand the clinical study and give written informed consent
排除标准
- •*History of major hemorrhage
- •* High risk of hemorrhage
- •* History of other malignancies
- •* Active ulcer
- •* Patients using anti-coagulants and fibrinolytic drugs
- •* Active Hepatitis B, or known HBs antigen positive
- •* Prior treatment history with thrombomodulin alfa
- •* Administration of another investigational medicinal product within 30 days prior to randomization
- •* Patient is pregnant (positive urine human chorionic gonadotropin) or breastfeeding or intends to get pregnant during the Treatment period
- •* Patients otherwise deemed as inappropriate to participate in the study by the Investigator
研究者
相似试验
招募中
1 期
A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric HypoglycaemiaCTIS2023-505316-37-00Recordati AG72
进行中（未招募）
1 期
A double-blind, randomized, placebo-controlled, dose finding study of R126638 given as a single or repeat dose in oral solution vs placebo in the treatment of pityriasis versicolor. - Dose finding study of R126638 in pityriasis versicolorEUCTR2005-004852-11-SEBarrier Therapeutics Inc.144
已完成
不适用
A double-blind, randomized, placebo-controlled, double-dummy, four-way crossover study to investigate the drug-drug interactions of almorexant and ethanol in healthy subjects.insomiasleeplessness10040998NL-OMON32705Actelion Pharmaceuticals20
已完成
不适用
A double-blind, randomized, placebo-controlled, double-dummy, four-way crossover study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy subjectsInsomniaNL-OMON45918Idorsia Pharmaceuticals LTD22
进行中（未招募）
1 期
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritisRheumatoid ArthritisEUCTR2016-004834-11-DKRottapharm Biotech S.r.l.240